Prometheus Biosciences
RXDX
$199.92
Share price
0.00%
Change (1 day)
360.96%
Change (1 year)
Categories
Operating Margin for Prometheus Biosciences (RXDX)
Operating Margin as of April 2024 (TTM): -4,028.93%
According to Prometheus Biosciences's latest financial reports and stock price the company's current Operating Margin is -4,028.93%. At the end of 2022 the company had an Operating Margin of -2,081.83%.
Operating Margin history for Prometheus Biosciences from 2020 to 2023
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2022 | -2,081.83% | -27.78% |
| 2021 | -2,882.55% | 13.77% |
| 2020 | -2,533.69% | 69.33% |
| 2019 | -1,496.33% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin differencediff. | Country |
|---|---|---|---|
 Epizyme EPZM | 0.00% | N/A | 🇺🇸 USA |
 Akebia Therapeutics AKBA | -20.79% | -99.48% | 🇺🇸 USA |
 Agenus
AGEN | -9.71% | -99.76% | 🇺🇸 USA |
What is a company's Operating Margin
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.